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Abstract
Background: This study aimed to investigate the relationship between an intensified low-density lipoprotein-
cholesterol (LDL-c) target of statin therapy and cancer risk.
Methods: Data from PUBMED, EMBASE, and the Cochrane Central Register of Controlled Trials as of September
2014 were searched for randomized controlled trials on statins. An intensified LDL-c target of <2.59 mmol/L
(100 mg/dL) or a relative LDL-c reduction by at least 30 % of the baseline was the primary criterion for all the trials
that were included in this meta-analysis. The I2 statistic was used to measure heterogeneity among the trials, and
risk estimates were calculated for cancer incidence in this random-effect meta-analysis.
Results: Nine eligible studies were identified with 59,571 participants, of whom 5379 developed cancer during the
follow-up period (2691 were given statins and 2688 were given control treatment). The intensified LDL-c target of
statin therapy did not affect cancer incidence (odds ratio, 1.00; 95 % confidence interval, 0.94 − 1.06; I2 = 1.6 %, p = 0.42),
which included some common cancers. Subgroup analysis showed that neither the chemical properties nor the variety
of the statins accounted for the residual variation in risk.
Conclusions: The intensified LDL-c target of statin therapy had no effect on the overall incidence of cancer, including
some common cancers. Therefore, intensified statin therapy does not need to be changed among adult clinical
patients.
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Introduction
Statin therapy has been proven to help prevent cardio-
vascular events and mortality [1–6]. Intensified low-
density lipoprotein-cholesterol (LDL-c) targets of statin
therapy, which are highly accurate, have also been widely
used in clinical practice, especially among high-risk pa-
tients. The third report of an expert panel on the detec-
tion, evaluation, and treatment of high blood cholesterol
in adults (Adult Treatment Panel ATP III, 2001) recom-
mended a LDL-c goal of < 100 mg/dL for patients with
coronary heart disease (CHD) and CHD risk equivalents
(10-year risk > 20 %; Framingham risk score) [7]. Among
diabetic patients, the dyslipidemia control criteria rec-
ommend LDL-c < 2.59 mmol/L for diabetic patients and
LDL-c < 2.07 mmol/L (80 mg/dL) for diabetic patients
with cardiovascular disease in China [8, 9]. The
American Association of Clinical Endocrinologists
2012 guidelines recommend LDL-c < 100 mg/dL for
high-risk patients (≥2 major risk factors and Framing-
ham risk score > 20 % CHD risk equivalent) [10]. The
intensified LDL-c target of statin therapy in this
meta-analysis was defined as a target of LDL-c <
2.59 mmol/L (100 mg/dL) or a relative LDL-c reduc-
tion of at least 30 % of the baseline [11].
Nevertheless, some side effects of statin therapy and
the intensified LDL-c target of statin therapy have been
reported (e.g., cancer risk). Several studies have reported
the relationship between statin therapy and cancer risk
[12–18]. A considerable amount of scholars believe that
statin therapy has no relationship with cancer risk or
statin therapy may prevent cancer, despite contradictory
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findings in the literature [15–18]. For instance, a signifi-
cant decrease in HR-negative breast cancer was reported
among statin users in a previous study [15]. A recently
published systematic review and meta-analysis reported
that statins have no effect on the overall incidence of
cancer [17]. Few studies investigated the correlation
between the intensified LDL-c target of statin therapy
and cancer risk, but the same indefinite conclusion was
obtained. Low risk of cancer was found for patients
treated with high-efficacy statins in a recent population-
based study (LDL-c reduction: low, ≤30 %; moderate,
31–40 %; high, ≥41 %) [19, 20]. However, a previous
study showed that cancer incidence did not increase in
the group achieving LDL-C < 30 mg/dL after high-
intensity statin therapy compared with the controls [21].
The relationship between the intensified LDL-c target
of statin therapy and cancer risk has been investigated
for a long time, but results remain inconsistent. Thus,
we aimed to investigate whether the intensified LDL-c
target of statin therapy contributes to the onset of car-
cinoma according to the findings of previous meta-
analyses and recent randomized controlled trials (RCTs).
Methods
Ethics
The protocol of the current study was approved by the
research ethics committees of ZhongDa Hospital, which
was affiliated with Southeast University.
Search strategy
To obtain all of the original studies on the effect of
intensified LDL-c target of statin therapy on cancer inci-
dence in adult patients, we searched potentially eligible
studies in the electronic databases PUBMED, EMBASE,
and Cochrane as of September 2014. The following
medical subject headings and free text keywords were
used: “hydroxymethylglutaryl coenzyme A reductase
inhibitor,” “statins,” “statin,” “fluvastatin,” “mevastatin,”
“compactin,” “pravastatin,” “simvastatin,” “lovastatin,”
“pitavastatin,” “rosuvastatin,” “cerivastatin”, “atorvastatin,”
“cancer,” “carcinoma,” “neoplasm,” “tumor,” “phyma,”
“randomized controlled trial,” and “human”.
Selection criteria
We included the RCTs if one of the endpoint or study
assesses the effect of intensified LDL-c target of statin
therapy on cancer endpoints in adult patients. The in-
clusion criteria used for the search are described as fol-
lows. The study should be an original work comparing
statin treatment with an inactive control (placebo or no
statins) involving more than 1000 adult study partici-
pants (18 years and older) whose cancer incidence was
reported and followed-up for over one year. The patients
included in the report should have achieved an
intensified LDL-c target of < 2.59 mmol/L (100 mg/dl)
or a relative LDL-c reduction of at least 30 % of the
baseline. We excluded comparison trials involving either
different statins or different doses of the same statin as
well as trials on patients with cancer.
Data sources
For all of the published trials, the following details were
recorded: study characteristics (study design and alloca-
tion), participants (baseline age, sample size, and accom-
panying disease), therapeutic intervention (type of statin,
dose of statin, and duration of therapy), and new cancer
cases. Moreover, we recorded the endpoint LDL-c con-
centrations and relative reduction in LDL-c concentra-
tions during the statin therapy to verify whether the
intensified LDL-c target of statin therapy correlates with
the incidence of cancer.
For trials with unpublished information, we formally
requested data using a question sheet. The questions
covered the number of incident cancer in specific sites
(e.g., central nervous system (CNS), skin, breast, respira-
tory, gastrointestinal, and hematological). However, the
replies were unclear, or no reply was received.
Statistical analysis
To determine the potential effects of the intensified
LDL-c target of statin therapy on the incidence of can-
cer, odds ratio (OR) and 95 % confidence interval (CI)
were used to compare the mean differences in each sub-
group separately. We evaluated the statistical heterogen-
eity between trials with the I2 statistic (with 95 % CIs),
which is derived from Cochran’s Q (100 × (Q-df)/Q) [22]
and provides a measure of the overall variation that is at-
tributed to between-trial heterogeneity. Random-effect
meta-analysis was performed instead of the fixed-effect
model because the former approach provides a more
conservative assessment (e.g., broad CIs) of the aver-
age effect size. Subgroup analyses were used to inves-
tigate the potential sources of heterogeneity between
trials. The factors that were investigated included the
type of statin, dose of statin, and relative reduction in
LDL-c concentrations. We analyzed the data with
Stata version 11.0.
A funnel plot and Egger’s test were used to test for
publication bias [23]. We conducted meta-analyses that
included all trials; different types of statin (simvastatin,
rosuvastatin, atorvastatin, pravastatin, and fluvastatin);
comparison trials with hydrophilic (pravastatin and rosu-
vastatin) and lipophilic (atorvastatin, simvastatin, and
fluvastatin) statins; trials with specific cancer according
to available date (respiratory, gastrointestinal, genitouri-
nary and CNS). Additionally, we performed the sensitiv-
ity analysis with Stata version 11.0.
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Results
Description of the studies
We identified nine trials involving 59,571 non-cancer
participants, of whom 5379 developed cancer (Fig. 1).
Five different statins were studied, with a follow-up
duration of 1.9–16.3 years. The characteristics of the
included studies are summarized in Tables 1 and 2.
Effects of the intensified LDL-c target of statin therapy on
the overall incidence of cancer
Any statin
The intensified LDL-c target of statin therapy did not
affect the overall incidence of cancer (OR, 1.00; 95 % CI,
0.94 − 1.06; I2 = 1.6 %, p = 0.42; Fig. 2). Among the nine
trials, only the PROSPER (pravastatin in elderly individ-
uals at risk of vascular disease) study [13] showed that
the intensified LDL-c target of pravastatin therapy pro-
moted cancer incidence (Fig. 2).
We also performed sensitivity analysis, which sug-
gested that the combination of all trials in the primary
analysis was appropriate. Additionally, we conducted a
funnel plot and Egger’s test for all nine trials and found
no underlying publication bias.
Different statins
The subgroup analyses of the individual statin that met
the intensified LDL-c target revealed no significant effect
on the incidence of cancer. Pravastatin therapy was
Fig. 1 Flow diagram of literature search to identify randomised placebo-controlled or standard care-controlled statin trials
Table 1 Characters for non-cancer participants in nine placebo-controlled and standard care-controlled statin trials




Age (years) Statin Jadad
Score
HPS 2011 20536 At increased risk of vascular events 16.3 40–80 simvastatin 40 mg 5
AURORA 2009 2773 With maintenance hemodialysis 3.2 50–80 rosuvastatin 10 mg 5
CARDS 2008 2838 With type 2 diabetes and no history
of coronary heart disease (CHD)
3.9 40–75 atorvastatin 10 mg 4
JUPITER 2008 17802 Healthy 1.9 50 years and
older
rosuvastatin 20 mg 6
GDDS 2005 1255 With type 2 diabetes receiving
maintenance hemodialysis
4 18–80 atorvastatin 20 mg 7
ALLIANCE 2004 2442 CHD patients with hyperlipidemia 4.3 61.1(atorvastotin)/
61.3(usual-care)
a maximum atorvastatin
dose of 80 mg/day
3
PROSPER 2002 5804 With a history of, or risk factors
for, vascular disease
3.2 70–82 pravastatin 40 mg 6
LIPS 2002 1677 After successful first
percutaneouscoronary
intervention (PCI)
3.9 18–80 fluvastatin 80 mg 6
4S 1994 4444 With CHD 5.4 35–70 simvastatin 20 mg 5
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Table 2 Characters for non-cancer participants in nine placebo-controlled and standard care-controlled statin trials
















genitourinary, respiratory et al.
32.35 % 2.3 3493 10269 10267 1749 1744
AURORA Not specified 43 % 1.1 225 1389 1384 107 118
CARDS Not specified below
2.59 mmol/L
1.99 141 1428 1410 69 72
JUPITER Not specified 49 % 1.42 612 8901 8901 298 314
GDDS Not specified 42 % 1.86 83 619 636 39 44
ALLIANCE Not specified 34.30 % 2.5 144 1217 1225 67 77
PROSPER Gastrointestinal, genitourinary,
respiratory et al.
34 % 2.5 444 2891 2913 245 199
LIPS Gastrointestinal, genitourinary,
respiratory, CNS et al.
below
2.59 mmol/L
2.48 32 844 833 14 18
4S Gastrointestinal 35 % 3.17 205 2221 2223 103 102
TOTAL 5379 29779 29792 2691 2688
Fig. 2 Association between intensified LDL-c target of statin therapy and incident cancer in 9 major trials. Legend: The intensified LDL-c target of
statin therapy has no effect on the overall incidence of cancer
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found to promote cancer incidence (OR, 1.26; 95 % CI,
1.04 − 1.53). The subgroup analyses of fluvastatin ther-
apy [24] showed no effects on cancer incidence (OR,
0.76; 95 % CI, 0.38 − 1.55). This result (Fig. 3) was simi-
lar to that of simvastatin therapy (OR, 1.00; 95 % CI,
0.94–1.08; I2 = 0.0 %, p = 0.957) [25, 26], rosuvastatin
therapy (OR, 0.93; 95 % CI, 0.81 − 1.07; I2 = 0.0 %,
p = 0.728) [6, 27], and atorvastatin therapy (OR, 0.91;
95 % CI, 0.73 − 1.12; I2 = 0.0 %, p = 0.944) [28–30].
Lipophilic and hydrophilic statins
Given that the chemical properties of statins may lead to
different results from our previous findings, statins were
divided into two groups, namely, the lipophilic and
hydrophilic statins, in another subgroup analysis. Nei-
ther the lipophilic (OR, 0.99; 95 % CI, 0.93 − 1.06; Fig. 4).
nor hydrophilic (OR, 1.03; 95 % CI, 0.84 − 1.27; Fig. 4).
statins that met the intensified LDL-c target affected the
incidence of cancer.
Effects of the intensified LDL-c target of statin therapy on
cancer at specific sites
We also conducted subgroup analyses on site-specific
cancer. However, the available data are limited. We only
performed subgroup analyses on respiratory, CNS,
gastrointestinal, and genitourinary cancers based on the
present data. No relationship was found between the
intensified LDL-c target of statin therapy and the inci-
dence of respiratory cancer (OR, 1.05; 95 % CI, 0.91 −
1.21; I2 = 0.0 %, p = 0.794), CNS cancer (OR, 0.71; 95 %
CI, 0.09–5.55; I2 = 55.5 %, p = 0.134), gastrointestinal
cancer (OR, 1.11; 95 % CI, 0.80 − 1.54, I2 = 54.2 %,
p = 0.088), and genitourinary cancer (OR, 1.02; 95 % CI,
0.91 − 1.14; I2 = 0.0 %, p = 0.986).
Fig. 3 Association between different statins met intensified LDL-c target goal and incident cancer. Legend: The subgroup analyses of the individual
statin that met the intensified LDL-c target showed no significant effect on the incidence of cancer. Pravastatin therapy seemed to have favorable
promoting effect on cancer incidence. The subgroup analyses of fluvastatin, simvastatin, rosuvastatin and atorvastatin therapy showed no effect on
cancer incidence
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Discussion
The intensified LDL-c target of statin therapy, with the
goal of achieving LDL-c < 2.59 mmol/L (100 mg/dl) or a
relative LDL-c reduction by at least 30 % of the baseline
after statin treatment, is commonly used in clinical trials
and is believed to be effective. The intensified LDL-c tar-
get of statin therapy is suitable for the general popula-
tion. For example, according to previous reports, all
patients with peripheral arterial disease or those with fa-
milial hypercholesterolemia benefit from the intensified
LDL-c target of statin therapy [31, 32]. Furthermore, this
approach is appropriate and widely used in high-risk
populations, such as diabetics with cardiovascular and
cerebrovascular diseases. These patients are known to be
at high risk of cancer incidence, so lipid control appears
worthwhile. The dyslipidemia control criteria recom-
mend LDL-c < 2.59 mmol/L for diabetic patients, and
LDL-c < 2.07 mmol/L (80 mg/dL) for diabetic patients
with cardiovascular disease [8, 9]. Numerous studies
have explored the relationship between statins and
cancer incidence. However, reports on the effect of the
intensified LDL-c target of statin therapy on the inci-
dence of cancer are relatively few. The present compre-
hensive meta-analysis was performed to provide
evidence to clinicians and patients, which can also
improve patient compliance.
Our meta-analysis showed that the intensified LDL-c
target of statin therapy had no effect on the overall inci-
dence of cancer, including some common cancers. The
results of this meta-analysis were relatively stable ac-
cording to sensitivity analysis. Begg’s funnel plot and
Egger’s test showed no underlying publication bias.
In the studies selected for our meta-analysis, PROS-
PER [13] indicated that pravastatin may increase cancer
risk. However, when the authors of the PROSPER [13]
study extended their follow-up period to 14 years, no rela-
tionship was found between statin use and cancer risk
[33]. Another study showed that pravastatin therapy pre-
sented an increasing risk of cancer incidence with rising
patient age [34]. Nevertheless, the findings on pravastatin
Fig. 4 Lipophilic and hydrophilic statins and incident cancer. Legend: Neither the lipophilic nor hydrophilic statins that met the intensified LDL-c
target had effect on the incidence of cancer
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need to be confirmed by further studies. To date, clinical
statin therapy has no special significance according to our
subgroup analysis.
Previous studies have shown that statin therapy may
inhibit cancer. For example, a recent trial revealed that a
cumulative amount of statin use may decrease prostatic
cancer risk [35]. In a recently published study, lipophilic
statin was reported to play a therapeutic role in cancer
treatment [36]. Statins may inhibit HMG-CoA reductase
to lower the concentration of mevalonate, thereby de-
creasing the amount of isoprenylated intermediates that
are known to affect signaling pathways, from cancer
formation to progression [37].
Given the confusing association between statin therapy
and cancer risk, as well as increasing incidence of
cancer, we conducted subgroup analyses on site-
specific cancer. The results showed the absence of a
relationship between the intensified LDL-c target of
statin therapy and the incidence of respiratory, CNS,
gastrointestinal, and genitourinary cancers. To deter-
mine the safety of clinical statin treatment, we should
investigate the relationship between the intensified
LDL-c target of statin therapy and the risk of indivi-
dual cancers in the future.
Several limitations of our study should be noted. First,
the number of studies included in our meta-analysis is
limited, especially for some individual statin. Second,
sufficient evidence was unavailable to support or contra-
dict the finding that pravastatin may promote cancer in-
cidence. Third, available evidence from unpublished data
on site-specific cancer is limited.
Conclusion
The intensified LDL-c target of statin therapy did not
affect the overall incidence of cancer, including some
common cancers, among adult patients. Therefore, the
intensified therapy does not need to be changed among
adult patients in clinical applications.
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